



08-14-02

1621  
8/21/02  
AUG 19 2002  
TECH CENTER 1600/2900

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT**

Docket Number:  
1662/54903

Application Number  
10/000,428

Filing Date  
Nov. 30, 2001

Examiner  
To be  
Assigned

Art Unit  
1621

Invention Title  
CRYSTALLINE VENLAFAXINE BASE AND NOVEL  
POLYMORPHS OF VENLAFAXINE HYDROCHLORIDE,  
PROCESSES FOR PREPARING THEREOF

Inventor(s)  
DOLITZKY et al.

RECEIVED

Address to:  
Commissioner for Patents  
Washington D.C. 20231

I hereby certify that this correspondence is being deposited with the  
United States Postal Service as first class mail in an envelope  
addressed to: Commissioner for Patents, Washington, D.C. 20231,  
on

Date 8/12/02

Signature

Matthew Edmund  
KENYON & KENYON

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the following reference to the attention of the Examiner. This reference is listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.
3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge **Deposit Account No. 11-0600** for such fees. A copy of this communication is enclosed for charging purposes.

Dated: 8/12/02

By:

Siu K. Lo  
Siu K. Lo (Reg. No. 46,877)

KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)



|   |                                  |                          |
|---|----------------------------------|--------------------------|
| <b>SUPPLEMENTAL INFORMATION<br/>DISCLOSURE<br/>STATEMENT BY APPLICANT</b> | ATTY. DOCKET NO.<br>01662/54903  | SERIAL NO.<br>10/000,428 |
|   | APPLICANT<br>DOLITZKY et al.     |                          |
|   | FILING DATE<br>November 30, 2001 | GROUP<br>1621            |

RECEIVED  
AUG 19 2002  
TECH CENTER 1600/2900

U. S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL | PATENT<br>NUMBER | PATENT<br>DATE | NAME            | CLASS | SUB-<br>CLASS | FILING<br>DATE* |
|---------------------|------------------|----------------|-----------------|-------|---------------|-----------------|
|                     | 4,611,078        | Sept. 9, 1986  | Husbands et al. |       |               |                 |
|                     |                  |                |                 |       |               |                 |

\* - if pertinent

FOREIGN PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT<br>NUMBER | DATE         | COUNTRY | CLASS | SUBCLASS | TRANSLATION |    |
|---------------------|--------------------|--------------|---------|-------|----------|-------------|----|
|                     |                    |              |         |       |          | YES         | NO |
|                     | WO 00/32555        | June 8, 2000 | PCT     |       |          | N/A         |    |
|                     |                    |              |         |       |          |             |    |
|                     |                    |              |         |       |          |             |    |

OTHER DOCUMENTS

| EXAMINER<br>INITIAL |  | AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.   |
|---------------------|--|--|
|                     |  | J.P. Yardley, et al., 2-Phenyl-2-(1-hydroxycycloalkyl)ethylamine Derivatives: Synthesis and Antidepressant Activity, Journal of Medicinal Chemistry, 1990, 33, pp. 2899-2905 |
|                     |  |  |
|                     |  |  |

|   |                 |
|---|-----------------|
| EXAMINER  | DATE CONSIDERED |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. |                 |